RxDoctor Payments Data

Wayne Myers, DO

Surgery · Washington, PANPI 1932413325

Payments from drug & device makers

What this record shows

This record is dominated by education: $11,088 of the $15,042 with a category attached, or 73.7%. Intuitive Surgical accounts for 93.6% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $11,233 and has fallen 91.9% since, to $906 in 2025. Among surgery clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,042in general payments, 2019–2025

Across 135 payments — averaging $111.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$14K
  • Integra Lifesciences Corporation$450
  • Innocoll Pharmaceuticals Limited$122
  • Johnson & Johnson$94
  • Smith+Nephew$84
  • AstraZeneca$68
  • plus $143 from 6 others

What the payments were for

  • Travel & lodging$1,43710%
  • Food & beverage$2,11214%
  • Education$11,08874%
  • Other$4053%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,042 in reported general payments places this provider in the 90th percentile of 1,424 surgery providers in Pennsylvania.

See all surgery providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$47,566
Medicare patients
170
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.13$14,314
Pantoprazole Sodium29$247
Oxycodone Hcl45$141
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav16$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$84$14,31413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,424 surgery providers in Pennsylvania.

Other surgery in Washington

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →